The role of N-glycans in colorectal cancer progression: Potential biomarkers and therapeutic applications

Oncotarget

Volumn 7, Issue 15, 2016, Pages 19395-19413

  De Freitas Junior, Julio Cesar Madureira ^a   Morgado Díaz, José Andrés ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Biomarkers; Carcinoma; Colorectal cancer; Glycosylation; N glycans

Indexed keywords

ALPHA 2,6 SIALYLATED LACTOSAMINE; BETA 1,6 BRANCHED N GLYCAN; BETA CATENIN; CARBOHYDRATES AND CARBOHYDRATE DERIVATIVES; FUCOSE; GLYCAN; GLYCOSYLTRANSFERASE; MANNOSE N GLYCAN; N ACETYLGLUCOSAMINYLTRANSFERASE; N ACETYLLACTOSAMINE; PAUCIMANNOSE; PROTEIN B3GNT8; PROTEIN MGAT3; PROTEIN MGAT5; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN; WNT PROTEIN; ANTINEOPLASTIC AGENT; POLYSACCHARIDE;

CANCER GROWTH; CARBOHYDRATE SYNTHESIS; CELL ADHESION; CELL GROWTH; CELL INTERACTION; CELL INVASION; CLINICAL FEATURE; COLON CARCINOGENESIS; COLORECTAL CANCER; CYTOLOGY; DISEASE ASSOCIATION; EPIDEMIOLOGICAL DATA; EXTRACELLULAR MATRIX; GLYCOSYLATION; HUMAN; METABOLIC REGULATION; METASTASIS; NONHUMAN; PHENOTYPE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; SIALYLATION; SIGNAL TRANSDUCTION; TREATMENT INDICATION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CHEMISTRY; COLORECTAL TUMOR; DISEASE EXACERBATION; DRUG EFFECTS; METABOLISM; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; GLYCOSYLATION; HUMANS; MODELS, BIOLOGICAL; N-ACETYLGLUCOSAMINYLTRANSFERASES; POLYSACCHARIDES;

EID: 84964711861     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6283     Document Type: Review

References (120)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-917.
2. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471-4.
3. Terdiman JP, Conrad PG, Sleisenger MH. Genetic testing in hereditary colorectal cancer: indications and procedures. Am J Gastroenterol. 1999;94:2344-56.
4. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343:78-85.
5. Samowitz WS, Curtin K, Lin HH, Robertson MA, Schaffer D, Nichols M, Gruenthal K, Leppert MF, Slattery ML. The colon cancer burden of genetically defined hereditary nonpolyposis colon cancer. Gastroenterology. 2001;121:830-8.
6. Giardiello FM, Brensinger JD, Petersen GM. AGA technical review on hereditary colorectal cancer and genetic testing. Gastroenterology. 2001;121:198-213.
7. Wakai K, Kojima M, Tamakoshi K, Watanabe Y, Hayakawa N, Suzuki K, Hashimoto S, Kawado M, Tokudome S, Suzuki S, Ozasa K, Toyoshima H, Ito Y, Tamakoshi A, JACC Study Group. Alcohol consumption and colorectal cancer risk: findings from the JACC Study. J Epidemiol. 2005;15 Suppl 2:S173-9.
8. Dahm CC, Keogh RH, Spencer EA, Greenwood DC, Key TJ, Fentiman IS, Shipley MJ, Brunner EJ, Cade JE, Burley VJ, Mishra G, Stephen AM, Kuh D, White IR, Luben R, Lentjes MA, Khaw KT, Rodwell Bingham SA. Dietary fiber and colorectal cancer risk: a nested case-control study using food diaries. J Natl Cancer Inst. 2010;102:614-26.
9. Sarebø M, Skjelbred CF, Breistein R, Lothe IM, Hagen PC, Bock G, Hansteen IL, Kure EH. Association between cigarette smoking, APC mutations and the risk of developing sporadic colorectal adenomas and carcinomas. BMC Cancer. 2006;6:71.
10. Michor F, Iwasa Y, Lengauer C, Nowak MA. Dynamics of colorectal cancer. Semin Cancer Biol. 2005;15:484-93.
11. Sancho E, Batlle E, Clevers H. Signaling pathways in intestinal development and cancer. Annu Rev Cell Dev Biol. 2004;20:695-723.
12. Al-Sohaily S, Biankin A, Leong R, Kohonen-Corish M, Warusavitarne J. Molecular pathways in colorectal cancer. J Gastroenterol Hepatol. 2012;27:1423-31.
13. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol. 2010;28:1254-61.
14. Tighe A, Johnson VL, Taylor SS. Truncating APC mutations have dominant effects on proliferation, spindle checkpoint control, survival and chromosome stability. J Cell Sci. 2004;117:6339-53.
15. Medici D, Hay ED, Olsen BR. Snail and Slug promote epithelial-mesenchymal transition through beta-catenin-Tcell factor-4-dependent expression of transforming growth factor-beta3. Mol Biol Cell. 2008;19:4875-87.
16. Ye Q, Cai W, Zheng Y, Evers BM, She QB. ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer. Oncogene. 2014;33:1828-39.
17. Xu J, Attisano L. Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A. 2000;97:4820-5.
18. Lee H, Chin H, Kim K, Lee D. ERBB3 knockdown induces cell cycle arrest and activation of Bak and Bax-dependent apoptosis in colon cancer cells. Oncotarget. 2014;5:5138-52. doi: 10.18632/oncotarget.2094.
19. Gonsalves WI, Mahoney MR, Sargent DJ, Nelson GD, Alberts SR, Sinicrope FA, Goldberg RM, Limburg PJ, Thibodeau SN, Grothey A, Hubbard JM, Chan E, Nair S, Berenberg JL, McWilliams RR, Oncology AfCTi. Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst. 2014;106.
20. Khoury GA, Baliban RC, Floudas CA. Proteome-wide posttranslational modification statistics: frequency analysis and curation of the swiss-prot database. Sci Rep. 2011;1.
21. Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15:540-55.
22. Sasai K, Ikeda Y, Fujii T, Tsuda T, Taniguchi N. UDPGlcNAc concentration is an important factor in the biosynthesis of beta1, 6-branched oligosaccharides: regulation based on the kinetic properties of N-acetylglucosaminyltransferase V. Glycobiology. 2002;12:119-27.
23. Zhao Y, Nakagawa T, Itoh S, Inamori K, Isaji T, Kariya Y, Kondo A, Miyoshi E, Miyazaki K, Kawasaki N, Taniguchi N, Gu J. N-acetylglucosaminyltransferase III antagonizes the effect of N-acetylglucosaminyltransferase V on alpha3beta1 integrin-mediated cell migration. J Biol Chem. 2006;281:32122-30.
24. Cheung P, Dennis JW. Mgat5 and Pten interact to regulate cell growth and polarity. Glycobiology. 2007;17:767-73.
25. Partridge EA, Le Roy C, Di Guglielmo GM, Pawling J, Cheung P, Granovsky M, Nabi IR, Wrana JL, Dennis JW. Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science. 2004;306:120-4.
26. Hirabayashi J, Hashidate T, Arata Y, Nishi N, Nakamura T, Hirashima M, Urashima T, Oka T, Futai M, Muller WE, Yagi F, Kasai K. Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochim Biophys Acta. 2002;1572:232-54.
27. Lau KS, Partridge EA, Grigorian A, Silvescu CI, Reinhold VN, Demetriou M, Dennis JW. Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell. 2007;129:123-34.
28. Stanley P. A method to the madness of N-glycan complexity? Cell. 2007;129:27-9.
29. De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013;13:97-110.
30. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7:131-42.
31. Oliveira C, Sousa S, Pinheiro H, Karam R, Bordeira-Carriço R, Senz J, Kaurah P, Carvalho J, Pereira R, Gusmão L, Wen X, Cipriano MA, Yokota J, Carneiro F, Huntsman D, Seruca R. Quantification of epigenetic and genetic 2nd hits in CDH1 during hereditary diffuse gastric cancer syndrome progression. Gastroenterology. 2009;136:2137-48.
32. C Corso G, Carvalho J, Marrelli D, Vindigni C, Carvalho B, Seruca R, Roviello F, Oliveira C. Somatic mutations and deletions of the E-cadherin gene predict poor survival of patients with gastric cancer. J Clin Oncol. 2013;31:868-75.
33. Carvalho J, van Grieken NC, Pereira PM, Sousa S, Tijssen M, Buffart TE, Diosdado B, Grabsch H, Santos MA, Meijer G, Seruca R, Carvalho B, Oliveira C. Lack of microRNA-101 causes E-cadherin functional deregulation through EZH2 up-regulation in intestinal gastric cancer. J Pathol. 2012;228:31-44.
34. Paredes J, Figueiredo J, Albergaria A, Oliveira P, Carvalho J, Ribeiro AS, Caldeira J, Costa AM, Simões-Correia J, Oliveira MJ, Pinheiro H, Pinho SS, Mateus R, Reis CA, Leite M, Fernandes MS, Schmitt F, Carneiro F, Figueiredo C, Oliveira C, Seruca R. Epithelial E-and P-cadherins: role and clinical significance in cancer. Biochim Biophys Acta. 2012;1826:297-311.
35. Pinho SS, Seruca R, Gärtner F, Yamaguchi Y, Gu J, Taniguchi N, Reis CA. Modulation of E-cadherin function and dysfunction by N-glycosylation. Cell Mol Life Sci. 2011;68:1011-20.
36. Zhao H, Liang Y, Xu Z, Wang L, Zhou F, Li Z, Jin J, Yang Y, Fang Z, Hu Y, Zhang L, Su J, Zha X. N-glycosylation affects the adhesive function of E-Cadherin through modifying the composition of adherens junctions (AJs) in human breast carcinoma cell line MDA-MB-435. J Cell Biochem. 2008;104:162-75.
37. de Freitas Junior JC, Silva BUR, de Souza WF, de Araújo WM, Abdelhay ES, Morgado-Díaz JA. Inhibition of N-linked glycosylation by tunicamycin induces E-cadherinmediated cell-cell adhesion and inhibits cell proliferation in undifferentiated human colon cancer cells. Cancer Chemother Pharmacol. 2011;68:227-38.
38. Pinho SS, Reis CA, Paredes J, Magalhães AM, Ferreira AC, Figueiredo J, Xiaogang W, Carneiro F, Gärtner F, Seruca R. The role of N-acetylglucosaminyltransferase III and V in the post-transcriptional modifications of E-cadherin. Hum Mol Genet. 2009;18:2599-608.
39. Pinho SS, Osório H, Nita-Lazar M, Gomes J, Lopes C, Gärtner F, Reis CA. Role of E-cadherin N-glycosylation profile in a mammary tumor model. Biochem Biophys Res Commun. 2009;379:1091-6.
40. Pinho SS, Figueiredo J, Cabral J, Carvalho S, Dourado J, Magalhães A, Gärtner F, Mendonfa AM, Isaji T, Gu J, Carneiro F, Seruca R, Taniguchi N, Reis CA. E-cadherin and adherens-junctions stability in gastric carcinoma: functional implications of glycosyltransferases involving N-glycan branching biosynthesis, N-acetylglucosaminyltransferases III and V. Biochim Biophys Acta. 2013;1830:2690-700.
41. Yoshimura M, Ihara Y, Matsuzawa Y, Taniguchi N. Aberrant glycosylation of E-cadherin enhances cellcell binding to suppress metastasis. J Biol Chem. 1996;271:13811-5.
42. de-Freitas-Junior JC, Carvalho S, Dias AM, Oliveira P, Cabral J, Seruca R, Oliveira C, Morgado-Díaz JA, Reis CA, Pinho SS. Insulin/IGF-I signaling pathways enhances tumor cell invasion through bisecting GlcNAc N-glycans modulation. an interplay with E-cadherin. PLoS One. 2013;8:e81579.
43. Lagana A, Goetz JG, Cheung P, Raz A, Dennis JW, Nabi IR. Galectin binding to Mgat5-modified N-glycans regulates fibronectin matrix remodeling in tumor cells. Mol Cell Biol. 2006;26:3181-93.
44. Langer MD, Guo H, Shashikanth N, Pierce JM, Leckband DE. N-glycosylation alters cadherin-mediated intercellular binding kinetics. J Cell Sci. 2012;125:2478-85.
45. Li N, Xu H, Fan K, Liu X, Qi J, Zhao C, Yin P, Wang L, Li Z, Zha X. Altered β1, 6-GlcNAc branched N-glycans impair TGF-β-mediated Epithelial-to-Mesenchymal Transition through Smad signalling pathway in human lung cancer. J Cell Mol Med. 2014;18:1975-91.
46. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-74.
47. Granovsky M, Fata J, Pawling J, Muller WJ, Khokha R, Dennis JW. Suppression of tumor growth and metastasis in Mgat5-deficient mice. Nat Med. 2000;6:306-12.
48. Miwa HE, Koba WR, Fine EJ, Giricz O, Kenny PA, Stanley P. Bisected, complex N-glycans and galectins in mouse mammary tumor progression and human breast cancer. Glycobiology. 2013;23:1477-90.
49. Bhaumik M, Harris T, Sundaram S, Johnson L, Guttenplan J, Rogler C, Stanley P. Progression of hepatic neoplasms is severely retarded in mice lacking the bisecting N-acetylglucosamine on N-glycans: evidence for a glycoprotein factor that facilitates hepatic tumor progression. Cancer Res. 1998;58:2881-7.
50. Miyoshi E, Nishikawa A, Ihara Y, Gu J, Sugiyama T, Hayashi N, Fusamoto H, Kamada T, Taniguchi N. N-acetylglucosaminyltransferase III and V messenger RNA levels in LEC rats during hepatocarcinogenesis. Cancer Res. 1993;53:3899-902.
51. Ihara S, Miyoshi E, Ko JH, Murata K, Nakahara S, Honke K, Dickson RB, Lin CY, Taniguchi N. Prometastatic effect of N-acetylglucosaminyltransferase V is due to modification and stabilization of active matriptase by adding beta 1-6 GlcNAc branching. J Biol Chem. 2002;277:16960-7.
52. Ito Y, Akinaga A, Yamanaka K, Nakagawa T, Kondo A, Dickson RB, Lin CY, Miyauchi A, Taniguchi N, Miyoshi E. Co-expression of matriptase and N-acetylglucosaminyltransferase V in thyroid cancer tissues-its possible role in prolonged stability in vivo by aberrant glycosylation. Glycobiology. 2006;16:368-74.
53. Yamamoto E, Ino K, Miyoshi E, Shibata K, Takahashi N, Kajiyama H, Nawa A, Nomura S, Nagasaka T, Kikkawa F. Expression of N-acetylglucosaminyltransferase V in endometrial cancer correlates with poor prognosis. Br J Cancer. 2007;97:1538-44.
54. Takahashi N, Yamamoto E, Ino K, Miyoshi E, Nagasaka T, Kajiyama H, Shibata K, Nawa A, Kikkawa F. High expression of N-acetylglucosaminyltransferase V in mucinous tumors of the ovary. Oncol Rep. 2009;22:1027-32.
55. Ishimura H, Takahashi T, Nakagawa H, Nishimura S, Arai Y, Horikawa Y, Habuchi T, Miyoshi E, Kyan A, Hagisawa S, Ohyama C. N-acetylglucosaminyltransferase V and beta1-6 branching N-linked oligosaccharides are associated with good prognosis of patients with bladder cancer. Clin Cancer Res. 2006;12:2506-11.
56. Osumi D, Takahashi M, Miyoshi E, Yokoe S, Lee SH, Noda K, Nakamori S, Gu J, Ikeda Y, Kuroki Y, Sengoku K, Ishikawa M, Taniguchi N. Core fucosylation of E-cadherin enhances cell-cell adhesion in human colon carcinoma WiDr cells. Cancer Sci. 2009;100:888-95.
57. Akama R, Sato Y, Kariya Y, Isaji T, Fukuda T, Lu L, Taniguchi N, Ozawa M, Gu J. N-acetylglucosaminyltransferase III expression is regulated by cell-cell adhesion via the E-cadherin-catenin-actin complex. Proteomics. 2008;8:3221-8.
58. Xu Q, Isaji T, Lu Y, Gu W, Kondo M, Fukuda T, Du Y, Gu J. Roles of N-acetylglucosaminyltransferase III in epithelialto-mesenchymal transition induced by transforming growth factor β1 (TGF-β1) in epithelial cell lines. J Biol Chem. 2012;287:16563-74.
59. Xu Q, Akama R, Isaji T, Lu Y, Hashimoto H, Kariya Y, Fukuda T, Du Y, Gu J. Wnt/beta-catenin signaling downregulates N-acetylglucosaminyltransferase III expression: the implications of two mutually exclusive pathways for regulation. J Biol Chem. 2011;286:4310-8.
60. Kim YS, Ahn YH, Song KJ, Kang JG, Lee JH, Jeon SK, Kim HC, Yoo JS, Ko JH. Overexpression and β-1, 6-Nacetylglucosaminylation-initiated aberrant glycosylation of TIMP-1: a "double whammy" strategy in colon cancer progression. J Biol Chem. 2012;287:32467-78.
61. Lee JH, Kang JG, Song KJ, Jeon SK, Oh S, Kim YS, Ko JH. N-Acetylglucosaminyltransferase V triggers overexpression of MT1-MMP and reinforces the invasive/metastatic potential of cancer cells. Biochem Biophys Res Commun. 2013;431:658-63.
62. Guo H, Nagy T, Pierce M. Post-translational glycoprotein modifications regulate colon cancer stem cells and colon adenoma progression in Apc(min/+) mice through altered Wnt receptor signaling. J Biol Chem. 2014;289:31534-49.
63. Lu Y, Chaney W. Induction of N-acetylglucosaminyltransferase V by elevated expression of activated or proto-Ha-ras oncogenes. Mol Cell Biochem. 1993;122:85-92.
64. Dall'Olio F, Chiricolo M, Ceccarelli C, Minni F, Marrano D, Santini D. Beta-galactoside alpha2, 6 sialyltransferase in human colon cancer: contribution of multiple transcripts to regulation of enzyme activity and reactivity with Sambucus nigra agglutinin. Int J Cancer. 2000;88:58-65.
65. Dall'Olio F, Chiricolo M, Mariani E, Facchini A. Biosynthesis of the cancer-related sialyl-alpha 2, 6-lactosaminyl epitope in colon cancer cell lines expressing beta-galactoside alpha 2, 6-sialyltransferase under a constitutive promoter. Eur J Biochem. 2001;268:5876-84.
66. Chiricolo M, Malagolini N, Bonfiglioli S, Dall'Olio F. Phenotypic changes induced by expression of betagalactoside alpha2, 6 sialyltransferase I in the human colon cancer cell line SW948. Glycobiology. 2006;16:146-54.
67. Zhu Y, Srivatana U, Ullah A, Gagneja H, Berenson CS, Lance P. Suppression of a sialyltransferase by antisense DNA reduces invasiveness of human colon cancer cells in vitro. Biochim Biophys Acta. 2001;1536:148-60.
68. Seales EC, Jurado GA, Brunson BA, Wakefield JK, Frost AR, Bellis SL. Hypersialylation of beta1 integrins, observed in colon adenocarcinoma, may contribute to cancer progression by up-regulating cell motility. Cancer Res. 2005;65:4645-52.
69. Zhuo Y, Chammas R, Bellis SL. Sialylation of beta1 integrins blocks cell adhesion to galectin-3 and protects cells against galectin-3-induced apoptosis. J Biol Chem. 2008;283:22177-85.
70. Swindall AF, Londoño-Joshi AI, Schultz MJ, Fineberg N, Buchsbaum DJ, Bellis SL. ST6Gal-I protein expression is upregulated in human epithelial tumors and correlates with stem cell markers in normal tissues and colon cancer cell lines. Cancer Res. 2013;73:2368-78.
71. Dalziel M, Dall'Olio F, Mungul A, Piller V, Piller F. Ras oncogene induces beta-galactoside alpha2, 6-sialyltransferase (ST6Gal I) via a RalGEF-mediated signal to its housekeeping promoter. Eur J Biochem. 2004;271:3623-34.
72. Seales EC, Jurado GA, Singhal A, Bellis SL. Ras oncogene directs expression of a differentially sialylated, functionally altered beta1 integrin. Oncogene. 2003;22:7137-45.
73. Che MI, Huang J, Hung JS, Lin YC, Huang MJ, Lai HS, Hsu WM, Liang JT, Huang MC. β1, 4-N-acetylgalactosaminyltransferase III modulates cancer stemness through EGFR signaling pathway in colon cancer cells. Oncotarget. 2014;5:3673-84. doi: 10.18632/oncotarget.1981.
74. Moriwaki K, Noda K, Furukawa Y, Ohshima K, Uchiyama A, Nakagawa T, Taniguchi N, Daigo Y, Nakamura Y, Hayashi N, Miyoshi E. Deficiency of GMDS leads to escape from NK cell-mediated tumor surveillance through modulation of TRAIL signaling. Gastroenterology. 2009;137:188-98, 98.e1-2.
75. Nakayama K, Moriwaki K, Imai T, Shinzaki S, Kamada Y, Murata K, Miyoshi E. Mutation of GDP-mannose-4, 6-dehydratase in colorectal cancer metastasis. PLoS One. 2013;8:e70298.
76. Fernandes B, Sagman U, Auger M, Demetrio M, Dennis JW. Beta 1-6 branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia. Cancer Res. 1991;51:718-23.
77. Hägerbäumer P, Vieth M, Anders M, Schumacher U. Lectin Histochemistry Shows WGA, PHA-L and HPA Binding Increases During Progression of Human Colorectal Cancer. Anticancer Res. 2015;35:5333-9.
78. Seelentag WK, Li WP, Schmitz SF, Metzger U, Aeberhard P, Heitz PU, Roth J. Prognostic value of beta1, 6-branched oligosaccharides in human colorectal carcinoma. Cancer Res. 1998;58:5559-64.
79. Murata K, Miyoshi E, Kameyama M, Ishikawa O, Kabuto T, Sasaki Y, Hiratsuka M, Ohigashi H, Ishiguro S, Ito S, Honda H, Takemura F, Taniguchi N, Imaoka S. Expression of N-acetylglucosaminyltransferase V in colorectal cancer correlates with metastasis and poor prognosis. Clin Cancer Res. 2000;6:1772-7.
80. Petretti T, Kemmner W, Schulze B, Schlag PM. Altered mRNA expression of glycosyltransferases in human colorectal carcinomas and liver metastases. Gut. 2000;46:359-66.
81. Balog CI, Stavenhagen K, Fung WL, Koeleman CA, McDonnell LA, Verhoeven A, Mesker WE, Tollenaar RA, Deelder AM, Wuhrer M. N-glycosylation of colorectal cancer tissues: a liquid chromatography and mass spectrometry-based investigation. Mol Cell Proteomics. 2012;11:571-85.
82. Gebert J, Kloor M, Lee J, Lohr M, André S, Wagner R, Kopitz J, Gabius HJ. Colonic carcinogenesis along different genetic routes: glycophenotyping of tumor cases separated by microsatellite instability/stability. Histochem Cell Biol. 2012;138:339-50.
83. Sethi MK, Thaysen-Andersen M, Smith JT, Baker MS, Packer NH, Hancock WS, Fanayan S. Comparative N-glycan profiling of colorectal cancer cell lines reveals unique bisecting GlcNAc and α-2, 3-linked sialic acid determinants are associated with membrane proteins of the more metastatic/aggressive cell lines. J Proteome Res. 2014;13:277-88.
84. Ishida H, Togayachi A, Sakai T, Iwai T, Hiruma T, Sato T, Okubo R, Inaba N, Kudo T, Gotoh M, Shoda J, Tanaka N, Narimatsu H. A novel beta1, 3-Nacetylglucosaminyltransferase (beta3Gn-T8), which synthesizes poly-N-acetyllactosamine, is dramatically upregulated in colon cancer. FEBS Lett. 2005;579:71-8.
85. Kemmner W, Roefzaad C, Haensch W, Schlag PM. Glycosyltransferase expression in human colonic tissue examined by oligonucleotide arrays. Biochim Biophys Acta. 2003;1621:272-9.
86. Dall'Olio F, Malagolini N, di Stefano G, Minni F, Marrano D, Serafini-Cessi F. Increased CMP-NeuAc:Gal beta 1, 4GlcNAc-R alpha 2, 6 sialyltransferase activity in human colorectal cancer tissues. Int J Cancer. 1989;44:434-9.
87. Dall'Olio F, Trerè D. Expression of alpha 2, 6-sialylated sugar chains in normal and neoplastic colon tissues. Detection by digoxigenin-conjugated Sambucus nigra agglutinin. Eur J Histochem. 1993;37:257-65.
88. Fukasawa T, Asao T, Yamauchi H, Ide M, Tabe Y, Fujii T, Yamaguchi S, Tsutsumi S, Yazawa S, Kuwano H. Associated expression of a2, 3sialylated type 2 chain structures with lymph node metastasis in distal colorectal cancer. Surg Today. 2013;43:155-62.
89. Kaprio T, Satomaa T, Heiskanen A, Hokke CH, Deelder AM, Mustonen H, Hagström J, Carpen O, Saarinen J, Haglund C. N-glycomic profiling as a tool to separate rectal adenomas from carcinomas. Mol Cell Proteomics. 2015;14:277-88.
90. Qiu Y, Patwa TH, Xu L, Shedden K, Misek DE, Tuck M, Jin G, Ruffin MT, Turgeon DK, Synal S, Bresalier R, Marcon N, Brenner DE, Lubman DM. Plasma glycoprotein profiling for colorectal cancer biomarker identification by lectin glycoarray and lectin blot. J Proteome Res. 2008;7:1693-703.
91. Gloster TM, Vocadlo DJ. Developing inhibitors of glycan processing enzymes as tools for enabling glycobiology. Nat Chem Biol. 2012;8:683-94.
92. Rillahan CD, Antonopoulos A, Lefort CT, Sonon R, Azadi P, Ley K, Dell A, Haslam SM, Paulson JC. Global metabolic inhibitors of sialyl-and fucosyltransferases remodel the glycome. Nat Chem Biol. 2012;8:661-8.
93. Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer. 2005;5:526-42.
94. Contessa JN, Bhojani MS, Freeze HH, Ross BD, Rehemtulla A, Lawrence TS. Molecular imaging of N-linked glycosylation suggests glycan biosynthesis is a novel target for cancer therapy. Clin Cancer Res. 2010;16:3205-14.
95. Gerber-Lemaire S, Juillerat-Jeanneret L. Studies toward new anti-cancer strategies based on alpha-mannosidase inhibition. Chimia (Aarau). 2010;64:634-9.
96. Goss PE, Reid CL, Bailey D, Dennis JW. Phase IB clinical trial of the oligosaccharide processing inhibitor swainsonine in patients with advanced malignancies. Clin Cancer Res. 1997;3:1077-86.
97. Shaheen PE, Stadler W, Elson P, Knox J, Winquist E, Bukowski RM. Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinoma. Invest New Drugs. 2005;23:577-81.
98. Sun JY, Zhu MZ, Wang SW, Miao S, Xie YH, Wang JB. Inhibition of the growth of human gastric carcinoma in vivo and in vitro by swainsonine. Phytomedicine. 2007;14:353-9.
99. Hamaguchi J, Nakagawa H, Takahashi M, Kudo T, Kamiyama N, Sun B, Oshima T, Sato Y, Deguchi K, Todo S, Nishimura S. Swainsonine reduces 5-fluorouracil tolerance in the multistage resistance of colorectal cancer cell lines. Mol Cancer. 2007;6:58.
100. Shen L, Yu M, Xu X, Gao L, Ni J, Luo Z, Wu S. Knockdown of β3GnT8 reverses 5-fluorouracil resistance in human colorectal cancer cells via inhibition the biosynthesis of polylactosamine-type N-glycans. Int J Oncol. 2014;45:2560-8.
101. de-Freitas-Junior JC, Bastos LG, Freire-Neto CA, Rocher BD, Abdelhay ES, Morgado-Díaz JA. N-glycan biosynthesis inhibitors induce in vitro anticancer activity in colorectal cancer cells. J Cell Biochem. 2012;113:2957-66.
102. Spitale A, Franzetti-Pellanda A, Mazzola P, Richetti A, Mazzuchelli L, Bordoni A. Impact of preoperative radiotherapy on survival in locally advanced rectal cancer: an observational population-based study from the South of Switzerland. Eur J Cancer Prev. 2012;21:139-46.
103. Kleiman LB, Krebs AM, Kim SY, Hong TS, Haigis KM. Comparative analysis of radiosensitizers for K-RAS mutant rectal cancers. PLoS One. 2013;8:e82982.
104. Bastos LG, de Marcondes PG, de-Freitas-Junior JC, Leve F, Mencalha AL, de Souza WF, de Araujo WM, Tanaka MN, Abdelhay ES, Morgado-Díaz JA. Progeny From Irradiated Colorectal Cancer Cells Acquire an EMT-Like Phenotype and Activate Wnt/β-Catenin Pathway. J Cell Biochem. 2014;115:2175-87.
105. Lee M, Lee HJ, Seo WD, Park KH, Lee YS. Sialylation of integrin beta1 is involved in radiation-induced adhesion and migration in human colon cancer cells. Int J Radiat Oncol Biol Phys. 2010;76:1528-36.
106. Smith MI, Deshmukh M. Endoplasmic reticulum stressinduced apoptosis requires bax for commitment and Apaf-1 for execution in primary neurons. Cell Death Differ. 2007;14:1011-9.
107. Clarke R, Cook KL, Hu R, Facey CO, Tavassoly I, Schwartz JL, Baumann WT, Tyson JJ, Xuan J, Wang Y, Wärri A, Shajahan AN. Endoplasmic reticulum stress, the unfolded protein response, autophagy, and the integrated regulation of breast cancer cell fate. Cancer Res. 2012;72:1321-31.
108. Miyoshi E, Uozumi N, Noda K, Hayashi N, Hori M, Taniguchi N. Expression of alpha1-6 fucosyltransferase in rat tissues and human cancer cell lines. Int J Cancer. 1997;72:1117-21.
109. Khare V, Lang M, Dammann K, Campregher C, Lyakhovich A, Gasche C. Modulation of N-glycosylation by mesalamine facilitates membranous E-cadherin expression in colon epithelial cells. Biochem Pharmacol. 2014;87:312-20.
110. Croci DO, Cerliani JP, Dalotto-Moreno T, Méndez-Huergo SP, Mascanfroni ID, Dergan-Dylon S, Toscano MA, Caramelo JJ, García-Vallejo JJ, Ouyang J, Mesri EA, Junttila MR, Bais C, Shipp MA, Salatino M, Rabinovich GA. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell. 2014;156:744-58.
111. Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29:2011-9.
112. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704-15.
113. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5:275-84.
114. O'Connor ML, Xiang D, Shigdar S, Macdonald J, Li Y, Wang T, Pu C, Wang Z, Qiao L, Duan W. Cancer stem cells: A contentious hypothesis now moving forward. Cancer Lett. 2014;344:180-7.
115. Mak AB, Blakely KM, Williams RA, Penttilä PA, Shukalyuk AI, Osman KT, Kasimer D, Ketela T, Moffat J. CD133 protein N-glycosylation processing contributes to cell surface recognition of the primitive cell marker AC133 epitope. J Biol Chem. 2011;286:41046-56.
116. Zhao YP, Ruan CP, Wang H, Hu ZQ, Fang M, Gu X, Ji J, Zhao JY, Gao CF. Identification and assessment of new biomarkers for colorectal cancer with serum N-glycan profiling. Cancer. 2012;118:639-50.
117. Hua S, An HJ. Glycoscience aids in biomarker discovery. BMB Rep. 2012;45:323-30.
118. Hirabayashi J, Yamada M, Kuno A, Tateno H. Lectin microarrays: concept, principle and applications. Chem Soc Rev. 2013;42:4443-58.
119. Kasper BT, Koppolu S, Mahal LK. Insights into miRNA regulation of the human glycome. Biochem Biophys Res Commun. 2014;445:774-9.
120. Gu J, Isaji T, Xu Q, Kariya Y, Gu W, Fukuda T, Du Y. Potential roles of N-glycosylation in cell adhesion. Glycoconj J. 2012;29:599-607.